Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists

Journal of Neurochemistry

Volumn 72, Issue 2, 1999, Pages 682-692

  Morissette, Marc ^a,b   Grondin, Richard ^a,b   Goulet, Martin ^a,b   Bédard, Paul J ^a,b   Di Paolo, Thérèse ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Cabergoline; Dyskinesia; MPTP lesioned monkey; Preproenkephalin; Preprotachykinin; SKF 82958

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 ALLYL 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; CABERGOLINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; MESSENGER RNA; PREPROENKEPHALIN; PREPROTACHYKININ;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; CAUDATE NUCLEUS; CONTROLLED STUDY; CORPUS STRIATUM; DENERVATION; DYSKINESIA; FEMALE; MONKEY; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUTAMEN; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032902460     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1999.0720682.x     Document Type: Article

References (65)

1. Andersen P. H. and Jansen J. A. (1990) Dopamine receptor agonists: selectivity and dopamine D1 receptor efficacy. Eur. J. Pharmacol. 188, 335-347.
2. Angulo J. A., Davis L. G., Burkhart B. A., and Christoph G. R. (1986) Reduction of striatal dopaminergic neurotransmission elevates striatal proenkephalin mRNA. Eur. J. Pharmacol. 130, 341-343.
3. 1-like receptor activation excites rat striatal large aspiny neurons in vitro. J. Neurosci. 18, 5180-5190.
4. Asselin M.-C., Soghomonian J. J., Côté P.-Y., and Parent A. (1994) Striatal changes in preproenkephalin mRNA levels in parkinsonian monkeys. Neuroreport 5, 2137-2140.
5. Augood S. J., Emson P. C., Mitchell I. J., Boyce S., Clarke C. E., and Crossman A. R. (1989) Cellular localisation of enkephalin gene expression in MPTP-treated cynomolgus monkeys. Mol. Brain Res. 6, 85-92.
6. 3H-spiper-one binding. Brain Res. 379, 294-299.
7. Bekenstein J. W. and Wooten G. F. (1989) Hemicholinium-3 binding sites in rat brain: a quantitative autoradiographic study. Brain Res. 481, 97-105.
8. 3H]SCH23390 binding to D1 dopamine receptors in the basal ganglia of the cat and primate: delineation of striosomal compartments and pallidal and nigral subdivisions. Neuroscience 26, 101-119.
9. Blanchet P. J., Gomez-Mancilla B., Di Paolo T., and Bédard P. J (1995) Is striatal dopaminergic receptor imbalance responsible for levodopa-induced dyskinesias? Fundam. Clin. Pharmacol. 9, 434-442.
10. Blanchet P. J., Grondin R., and Bédard P. J. (1996) Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates. Mov. Disord. 11, 91-94.
11. Braun A., Fabbrini G., Mouradian M. M., Serrati C., Barone P., and Chase T. N. (1987) Selective D-1 dopamine receptor agonist treatment in Parkinson's disease. J. Neural Transm. 68, 41-50.
12. Brotchie J. M., Henry B., and Crossman A. R. (1997) Topographically-organized changes in opioid peptide synthesis may underlie dyskinesia/dystonia induced by prolonged dopamine replacement therapy in animal models of Parkinson's disease. (Abstr.) Mov. Disord. 12, 11.
13. Campbell K. and Bjorklund A. (1994) Prefrontal cortico-striatal afferents maintain increased enkephalin gene expression in the dopamine-denervated rat striatum. Eur. J. Neurosci. 6, 1371-1383.
14. Comb M., Seeburg P. H., Adelman J., Eiden L., and Herbert E. (1982) Primary structure of the human Met- and Leu-enkephalin precursor and its mRNA. Nature 295, 663-666.
15. Dacko S. and Schneider J. S. (1991) Met-enkephalin immunoreactivity in the basal ganglia in symptomatic and asymptomatic MPTP-exposed monkeys: correlation with degree of parkinsonian symptoms. Neurosci. Lett. 127, 49-52.
16. Engber T. M., Susel Z., Kuo S., and Chase T. N. (1990) Chronic levodopa treatment alters basal and dopamine agonist-stimulated cerebral glucose utilization. J. Neurosci. 10, 3889-3895.
17. Engber T. M., Susel Z., Kuo S., Gerfen C. R., and Chase T. N. (1991) Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats. Brain Res. 552, 113-118.
18. Filion M. and Tremblay L. (1991) Abnormal spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Res. 547, 142-151.
19. Gerfen C. R., Engber T. M., Mahan L. C., Susel Z., Chase T. N., Monsma F. J., and Sibley D. R. (1990) D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250, 1429-1432.
20. Gomez-Mancilla B., Boucher R., Gagnon C., Di Paolo T., Markstein R., and Bédard P. J. (1993) Effect of adding the D-1 agonist CY 208-243 to chronic bromocriptine treatment. I. Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors. Mov. Disord. 8, 144-150.
21. Goto S., Hirano A., and Matsumoto S. (1990) Met-enkephalin immunoreactivity in the basal ganglia in Parkinson's disease and striatonigral degeneration. Neurology 40, 1051-1056.
22. Goulet M., Grondin R., Blanchet P. J, Bédard P. J., and Di Paolo T. (1996) Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys. Brain Res. 719, 129-137.
23. Goulet M., Morissette M., Calon F., Blanchet P. J., Falardeau P., Bédard P. J., and Di Paolo T. (1997) Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: in situ hybridization histochemical analysis. Neuroscience 79, 497-507.
24. Grafe M. R., Forno L. S., and Eng L. F. (1985) Immunocytochemical studies of substance P and met-enkephalin in the basal ganglia and substantia nigra in Huntington's, Parkinson's and Alzheimer's diseases. J. Neuropathol. Exp. Neurol. 44, 47-59.
25. Granata R., Wenning G. K., Jolkkonen J., Jenner P., and Marsden C. D. (1996) Effect of repeated administration of dopamine agonists on striatal neuropeptide mRNA expression in rats with a unilateral nigral 6-hydroxydopamine lesion. J. Neural Transm. 103, 249-260.
26. Grondin R., Goulet M., Di Paolo T., and Bédard P. J. (1996) Cabergoline, a long-acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates. Brain Res. 735, 298-306.
27. Hajji M. D., Salin P., and Kerkerian-Le Goff L. (1996) Chronic dizocilpine maleate (MK-801) treatment suppresses the effects of nigrostriatal dopamine deafferentation on enkephalin but not on substance P expression in the rat striatum. Eur. J. Neurosci. 8, 917-926.
28. 3H]hemicholinium-3. J. Comp. Neurol. 321, 591-611.
29. Haverstick D. M., Rubenstein A., and Bannon M. J. (1989) Striatal tachykinin gene expression regulated by interaction of D-1 and D-2 dopamine receptors. J. Pharmacol. Exp. Ther. 248, 858-862.
30. Herrero M. T., Augood S. J., Hirsch E. C., Javoy-Agid F., Luquin M. R., Agid Y., Obeso J. A., and Emson P. C. (1995) Effects of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum. Neuroscience 68, 1189-1198.
31. Jiang H.-K., McGinty J. F., and Hong J. S. (1990) Differential modulation of striatonigral dynorphin and enkephalin by dopamine receptor subtypes. Brain Res. 507, 57-64.
32. Jolkkonen J., Granata R., Jenner P., and Marsden C. D. (1995a) Acute and subchronic effect of dopamine agonists on neuropeptide gene expression in the rat striatum. Neuropeptides 29, 109-114.
33. Jolkkonen J., Jenner P., and Marsden C. D. (1995A) L-DOPA reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP. Mol. Brain Res. 32, 297-307.
34. Lahti R. A., Roberts R. C., and Tamminga C. A. (1995) D2-family receptor distribution in human postmortem tissue: an autoradiographic study. Neuroreport 6, 2502-2512.
35. Le Moine C. and Bloch B. (1995) D1 and D2 dopamine receptor gene expression in the rat striatum: sensitive cRNA probes demonstrate prominent segregation of D1 and D2 mRNAs in distinct neuronal populations of the dorsal and ventral striatum. J. Comp. Neurol. 355, 418-426.
36. Li S. C., Schoenberg B. S., Wang C. C., Cheng X. M., Rui D. Y., Bolis C. L., and Schoenberg D. G. (1985) A prevalence survey of Parkinson's disease and other movement disorders in the People's Republic of China. Arch. Neurol. 42, 655-657.
37. Maneuf Y. P., Mitchell I. J., Crossman A. R., and Brotchie J. M. (1994) On the role of enkephalin cotransmission in the GABAergic striatal efferents of the globus pallidus. Exp. Neurol. 125, 65-71.
38. Mauborgne A., Javoy-Agid F., Legrand J. C., Agid Y., and Cesselin F. (1983) Decrease of substance P-like immunoreactivity in the substantia nigra and pallidum of parkinsonian brains. Brain Res. 268, 167-170.
39. Mitchell I. J., Clarke C. E., Boyce S., Robertson R. G., Peggs D., Sambrook M. A., and Crossman A. R. (1989) Neural mechanism underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3.6-tetrahydropyridine. Neuroscience 32, 213-226.
40. Mitchell I. J., Boyce S., Sambrook M. A., and Crossman A. R. (1992) A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia. Brain 115, 809-824.
41. Morissette M., Goulet M., Soghomonian J.-J., Blanchet P. J., Calon F., Bédard P. J., and Di Paolo T. (1997) Preproenkephalin messenger RNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy. Mol. Brain Res. 49, 55-62.
42. 1 dopamine receptor antagonist. Neurosci. Lett. 125, 201-204.
43. Morris B. J., Hollt V., and Herz A. (1988) Dopaminergic regulation of striatal proenkephalin mRNA and prodynorphin mRNA: contrasting effects of D1 and D2 antagonists. Neuroscience 25, 525-532.
44. Nisbet A. P., Foster O. J., Kingsbury A., Eve D. J., Daniel S. E., Marsden C. D., and Lees A. J. (1995) Preproenkephalin and preprotachykinin messenger RNA expression in normal basal ganglia and in Parkinson's disease. Neuroscience 66, 361-376.
45. Nisenbaum L. K., Kitai S., Crowley W., and Gerfen C. R. (1994) Temporal dissociation between changes in striatal enkephalin and substance P messenger RNAs following striatal dopamine depletion. Neuroscience 60, 927-937.
46. Papa S. M. and Chase T. N. (1996) Levodopa-induced dyskinesia improved by a glutamate antagonist in parkinsonian monkeys. Ann. Neurol. 39, 574-578.
47. Parent A. (1990) Extrinsic connection of the basal ganglia. Trends Neurosci. 13, 254-258.
48. Pollack A. E. and Wooten F. G. (1992) Differential regulation of striatal preproenkephalin mRNA by D1 and D2 dopamine receptors. Mol. Brain Res. 12, 111-119.
49. Richfield E. K., Young A. B., and Penney J. B. (1987) Comparative-distribution of dopamine D1 and D2 receptors in the basal ganglia of turtles, pigeons, rats, cats and monkeys. J. Comp. Neurol. 262, 446-463.
50. Salin P., Hajji M. D., and Kerkerian-Le Goff L. (1996) Bilateral 6-hydroxydopamine-induced lesion of the nigrostriatal dopamine pathway reproduced the effects of unilateral lesion on substance P but not on enkephalin expression in rat basal ganglia. Eur. J. Neurosci. 8, 1746-1757.
51. Salin P., Dziewczapolski G., Gershanik O. S., Nieoullon A., and Raisman-Vozari R. (1997) Differential regional effects of long-term L-DOPA treatment on preproenkephalin and preprotachykinin gene expression in the striatum of 6-hydroxydopamine-lesioned rat. Mol. Brain Res. 47, 311-321.
52. Sibley D. R. and Monsma F. J. Jr. (1992) Molecular biology of dopamine receptors. Trends Pharmacol. Sci. 13, 61-69.
53. Smith A. D. and Bolam P. (1990) The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones. Trends Neurosci. 13, 259-265.
54. Strange P. G. (1995) Dopamine receptors in the basal ganglia: relevance to Parkinson's disease. Mov. Disord. 8, 263-270.
55. Surmeier D. J., Song W. J., and Yan Z. (1996) Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. J. Neurosci. 16, 6579-6591.
56. Szabo J. and Cowan W. M. (1984) A sterotaxic atlas of the brain of the cynomolgus monkey (Macaca fascicularis). J. Comp. Neurol. 222, 265-300.
57. Taquet H., Nomoto M., Rose S., Jenner P., Javoy-Agid F., Mauborgne A., Benoliel J. J., Legrand J. C., and Agid Y. (1988) Levels of Met-enkephalin, Leu-enkephalin, substance P and cholecystokinin in the brain of the common marmoset following long term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment. Neuropeptides 12, 105-110.
58. Taylor M. D., De Ceballos M. L., Rose S., Jenner P., and Marsden C. D. (1992) Effects of a unilateral 6-hydroxydopamine lesion and prolonged L-3,4-dihydroxyphenylalanine treatment on peptidergic systems in rat basal ganglia. Eur. J. Pharmacol. 219, 183-192.
59. Voorn P., Roest G., and Groenewegen H. J. (1987) Increase of enkephalin and decrease of substance P immunoreactivity in the dorsal and ventral striatum of the rat after midbrain 6-hydroxydopamine lesions. Brain Res. 412, 391-396.
60. 2 receptor regulation of preproenkephalin and preprodynorphin mRNA in rat striatum following acute injection of amphetamine or methamphetamine. Synapse 22, 114-122.
61. Wang J. Q. and McGinty J. F. (1996b) Muscarinic receptors regulate striatal neuropeptide gene expression in normal and amphetaminetreated rats. Neuroscience 75, 43-56.
62. Wang J. Q. and McGinty J. F. (1997) The full D1 dopamine receptor agonist SKF-82958 induces neuropeptide mRNA in the normosensitive striatum of rats: regulation of D1/D2 interactions by muscarinic receptors. J. Pharmacol. Exp. Ther. 281, 972-982.
63. Young W. S. III, Bonner T. I., and Brann M. R. (1986) Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain. Proc. Natl Acad. Sci. USA 83, 9827-9831.
64. Yung K. K., Smith A. D., Levy A. I., and Bolam J. P. (1996) Synaptic connections between spiny neurons of the direct and indirect pathways in the neostriatum of the rat: evidence from dopamine receptor and neuropeptide immunostaining. Eur. J. Neurosci. 8, 861-869.
65. Zeng B.-Y., Jolkkonen J., Jenner P., and Marsden C. D. (1995) Chronic L-DOPA treatment differentially regulates gene expression of glutamate decarboxylase preproenkephalin and preprotachykinin in the striatum of 6-hydroxydopamine-lesioned rat. Neuroscience 66, 19-28.